Logo image of TCBP

TC BIOPHARM HOLDINGS PLC-ADR (TCBP) Stock Fundamental Analysis

USA - NASDAQ:TCBP - US87807D6085 - ADR

0.5 USD
-1.04 (-67.53%)
Last: 3/21/2025, 8:00:01 PM
0.6701 USD
+0.17 (+34.02%)
After Hours: 3/21/2025, 8:00:01 PM
Fundamental Rating

1

Taking everything into account, TCBP scores 1 out of 10 in our fundamental rating. TCBP was compared to 540 industry peers in the Biotechnology industry. Both the profitability and financial health of TCBP have multiple concerns. TCBP is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

TCBP had negative earnings in the past year.
TCBP had a negative operating cash flow in the past year.
In the past 5 years TCBP always reported negative net income.
In the past 5 years TCBP always reported negative operating cash flow.
TCBP Yearly Net Income VS EBIT VS OCF VS FCFTCBP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -5M -10M

1.2 Ratios

TCBP has a worse Return On Assets (-71.77%) than 65.09% of its industry peers.
Looking at the Return On Equity, with a value of -293.88%, TCBP is doing worse than 73.68% of the companies in the same industry.
Industry RankSector Rank
ROA -71.77%
ROE -293.88%
ROIC N/A
ROA(3y)-82.72%
ROA(5y)-76.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TCBP Yearly ROA, ROE, ROICTCBP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 1K 2K 3K 4K

1.3 Margins

TCBP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TCBP Yearly Profit, Operating, Gross MarginsTCBP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 -200 -400 -600

More info and screens

1

2. Health

2.1 Basic Checks

TCBP does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TCBP has more shares outstanding
There is no outstanding debt for TCBP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TCBP Yearly Shares OutstandingTCBP Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B
TCBP Yearly Total Debt VS Total AssetsTCBP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 5M 10M 15M

2.2 Solvency

TCBP has an Altman-Z score of -8.08. This is a bad value and indicates that TCBP is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of TCBP (-8.08) is worse than 69.47% of its industry peers.
A Debt/Equity ratio of 1.07 is on the high side and indicates that TCBP has dependencies on debt financing.
With a Debt to Equity ratio value of 1.07, TCBP is not doing good in the industry: 78.07% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.07
Debt/FCF N/A
Altman-Z -8.08
ROIC/WACCN/A
WACC6.34%
TCBP Yearly LT Debt VS Equity VS FCFTCBP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 -5M -10M -15M

2.3 Liquidity

A Current Ratio of 1.09 indicates that TCBP should not have too much problems paying its short term obligations.
TCBP has a worse Current ratio (1.09) than 87.19% of its industry peers.
TCBP has a Quick Ratio of 1.09. This is a normal value and indicates that TCBP is financially healthy and should not expect problems in meeting its short term obligations.
TCBP has a worse Quick ratio (1.09) than 85.09% of its industry peers.
Industry RankSector Rank
Current Ratio 1.09
Quick Ratio 1.09
TCBP Yearly Current Assets VS Current LiabilitesTCBP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 5M 10M 15M 20M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for TCBP have decreased strongly by -27216.05% in the last year.
TCBP shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)-27216.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%454.43%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, TCBP will show a very strong growth in Earnings Per Share. The EPS will grow by 41.42% on average per year.
TCBP is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -41.42% yearly.
EPS Next Y96.52%
EPS Next 2Y41.42%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

TCBP Yearly Revenue VS EstimatesTCBP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 1M 2M 3M
TCBP Yearly EPS VS EstimatesTCBP Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 -10K -20K -30K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TCBP. In the last year negative earnings were reported.
Also next year TCBP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TCBP Price Earnings VS Forward Price EarningsTCBP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TCBP Per share dataTCBP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4

4.3 Compensation for Growth

TCBP's earnings are expected to grow with 41.42% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.42%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

TCBP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TC BIOPHARM HOLDINGS PLC-ADR

NASDAQ:TCBP (3/21/2025, 8:00:01 PM)

After market: 0.6701 +0.17 (+34.02%)

0.5

-1.04 (-67.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)12-13 2022-12-13/bmo
Inst OwnersN/A
Inst Owner Change0%
Ins OwnersN/A
Ins Owner Change0%
Market Cap5.13M
Analysts82.86
Price Target48.96 (9692%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1500%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-1500%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.97
P/tB 2.81
EV/EBITDA N/A
EPS(TTM)-4.21
EYN/A
EPS(NY)-0.21
Fwd EYN/A
FCF(TTM)-1.61
FCFYN/A
OCF(TTM)-1.54
OCFYN/A
SpS0
BVpS0.25
TBVpS0.18
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -71.77%
ROE -293.88%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-82.72%
ROA(5y)-76.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 1.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.09
Quick Ratio 1.09
Altman-Z -8.08
F-Score1
WACC6.34%
ROIC/WACCN/A
Cap/Depr(3y)28.29%
Cap/Depr(5y)69.6%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-27216.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%454.43%
EPS Next Y96.52%
EPS Next 2Y41.42%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-19.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.79%
OCF growth 3YN/A
OCF growth 5YN/A